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KESAN BERBAGAI JENIS GELUCIRE TERHADAP PRESTASI 
PELEPASAN MANIK KALSIUM ALGINAT 
ABSTRAK 
Natrium Alginat merupakan polimer asli yang banyak digunakan dalam industri 
farmaseutikal. Penambahbaikan terhadap sifat-sifat polimer ini penting untuk 
keberkesanan dan penggunaannya yang meluas dengan bahan biologi dan drug yang 
berbeza. Gelucire merupakan keluarga sebatian yang disediakan daripada 
poliethilena glikol dan minyak yang berbeza. Lipid yang terhasil mempunyai sifat 
pelepasan yang berbeza dan sesetengahnya digunakan sebagai agen pelepasan segera, 
contohnya Gelucire 44/14. Manik-manik terbentuk sebagai satu sistem baru yang 
menggunakan kedua-dua bahan utama ini disediakan melalui teknik "drop wise". 
Kajian dijalankan untuk mencirikan serta menilai manik-manik yang terhasil. Kajian 
tersebut termasuklah kajian pelarutan, kajian taburan saiz, kajian pengembungan, 
kajian mikroskopik, kajian pemerangkapan drug dan kajian kestabilan. Faktor utama 
yang mungkin mempengaruhi pelepasan drug dikaji menggunakan reka bentuk 
eksperimen Taguchi (larutan pekat kalsium klorida, larutan pekat natrium alginat, 
laju pengacauan, kaedah pengeringan) dan data dianalisis melalui satu program 
khusus (Design Expert®). Campuran kedua-dua bahan ini memberikan sifat 
pelepasan yang lebih baik dibandingkan dengan formula yang menggunakan hanya 
satu daripada bahan ini. Jenis Gelucire memainkan peranan yang penting dalam sifat 
pelepasaan (Gelucire 43/01 memberikan profil pelepasan yang lebih baik 
dibandingkan dengan Gelucire 50/13 dan Gelucire 44/14). Sifat pelepasan drug 
bertambah baik dan boleh kekal lebih lama dalam bentuk manik dibandingkan 
dengan pelepasan daripada manik kalsium alginat dan serakan pepejal Gelucire. 
Keadaan optimum bagi penyediaan manik adalah 10% CaCL2, 2% natrium alginat, 
1000 rpm dan Gelucire 43/01. Dengan menggunakan reka bentuk D optimum, 
nisbah drug terbaik dan nisbah Gelucire: alginat terbaik diramal melalui program 
(natrium alginat (larutan 2%) 90.16%: Gelucire (43/01) 7.95%: paracetamol 1.89%) 
dan bagi nifedipine (natrium alginat (larutan 2%) 90.14% : Gelucire (43/01) 7.90% : 
XX 
nifedipine 1.96%). Keputusan yang diramal diperiksa secara praktikal dan ia 
memberikan profil pelepasan yang optimum dibandingk:an dengan rumusan yang 
lain. U.S Pharmacopeia mencadangk:an bahawa tidak lebih 30% daripada drug 
sepatutnya dilarutkan dalam satu jam pertama, di antara 30% dan 55% pada jam 
keempat, tidak kurang 60% pada jam kelapan dan tidak kurang 80% drug 
sepatutnya dilarutkan selepas 12 jam. Formula akhir terletak dalam julat ini untuk 
kedua-dua model drug (paracetamol and nifedipine ). 
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EFFECT OF VARIUS TYPE OF GELUCIRE ON THE SUSTAINED 
RELEASE PERFORMANCE OF CALCIUM ALGINATE BEAD. 
ABSTRACT 
Sodium alginate is a widely used natural polymer in the pharmaceutical 
industry. hnprovement of the sustained release properties of this polymer is 
important due to its effectiveness and wide use with different biomaterials and drugs. 
Gelucires are a family of compounds prepared from the polyethylene glycol and 
different oils. These lipid excipients have different sustained release properties and 
some of them are used as immediate release agents e.g. Gelucire 44/14. Beads 
formed as a new system using these two main ingredients were prepared by the drop 
wise technique. Studies were carried out to characterize and evaluate the beads 
produced. They include the dissolution studies, size distribution studies, swelling 
studies, microscopic studies, drug entrapment studies and stability studies. The main 
factors which might affect the drug release were studied by using a Taguchi 
experimental design (Calcium chloride solution concentration, sodium alginate 
solution concentration, stirring speed, drying method) and the data was analyzed by a 
special program (Design Expert®). Mixing these two excipients give an improved 
sustained release properties compared to the formula which used only one of them. 
The Gelucire type plays an important role in the sustained release properties 
(Gelucire 43/01 give better sustained release profile compared to Gelucire 50/13 and 
Gelucire44/14). The drug sustained release property improved and it stayed for 
longer time in the beads formed compared to the release from calcium alginate beads 
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and Gelucire solid dispersions. The optimal conditions for preparing the beads were 
10% CaClz, 2% Sodium alginate, 1000 rpm, and Gelucire 43/01. By using the D 
optimal design the best drug ratio and the best Gelucire: alginate ratio was predicted 
by the program (sodium alginate (solution 2%) 90.16% : Gelucire (43/01) 7.95% : 
paracetamol 1.89%) and for nifedipine (sodium alginate (solution 2%) 90.14% : 
Gelucire {43/01) 7.90%: nifedipine 1.96%). The predicted results were examined 
practically and its give the optimal sustained release profile comparing to the other 
formulations. U.S Pharmacopeia recommend that not more than 30% of the drug 
should dissolved in !he first hour, between 30% and 55% at hour 4, not less than 60% 
at hour 8 and not less than 80% of the drug should dissolved after 12 hours. The 
dissolution of the final formula was within the recommended range for both model 
drugs (paracetamol and nifedipine). 
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1.0 Introduction 
CHAPTER I 
INTRODUCTION 
The formulation of a modified release drug product containing Gelucires and 
alginate as excipients requires a thorough understanding of biopharmaceutics and 
mechanisms of controlled release process by the lipid and polymer which are being 
used as controlled release agents. 
1.1 Biopharmaceutics 
According to the Encyclopedia of Pharmaceutical Technology (Swarbrick, 
2007), biopharmaceutic is defined as "the study of the interrelationship of the 
physicochemical properties of the drug [active pharmaceutical ingredient (API)] and 
the drug product (dosage form in which the drug is fabricated) based on the 
biological performance of the drug". Stability, solubility, pH and pK.a, crystalline 
form (polymorph), excipient interaction and compatibility of the API are studied 
against their pharmacokinetics and pharmacodynamic properties. Biopharmaceutics 
also encompasses the effect and/or the role of different manufacturing methods and 
technologies on the desired or expected performance of the drug product. By using 
different quantitative methods and applied mathematic techniques, such as 
theoretical models, biopharmaceutics can evaluate the effect of the drug substance, 
dosage form, and routes of drug administration on the therapeutic requirements of the 
active pharmaceutical ingredient and the dosage form in which the drug is fabricated 
in. It is also the study of the effect on a certain physiological environment. 
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Bioavailability is defined as "a measure of the rate and extent (amount) to 
which the active ingredient or active moiety becomes available at the site of action" 
(Swarbrick, 2007). It is a measure of the drug biological performance, the rate and 
extent of the systemically absorbed therapeutically active drug. Biopharmaceutics is 
also used to logically and scientifically design drug formulations to deliver the active 
pharmaceutical ingredient at a specific and desired rate to certain desired target organ 
or system to achieve the optimum therapeutic effect with minimal adverse reactions 
or side effects. 
Thus biopharmaceutics can be summarized to encomposed the following 
components: 
1. The physicochemical characteristics of the active drug substance. 
2. The physicochemical characteristics of the desired drug product. 
3. The considerations of the anatomy and physiology of the human body. 
4. The knowledge of the pharmacodynamics of the drug including the desired 
onset of time, duration and intensity of clinical response. 
5. The knowledge of the pharmacokinetics of the drug including absorption 
distribution, elimination and target drug concentration. 
Biopharmaceutics also involves studies of factors that influence the 
protection and stability of the drug within the product, the rate of drug release from 
the drug product, the rate of dissolution of the drug at the absorption site and the 
availability of the drug at its site of action 
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1.1.1 Biopharmaceutical considerations in drug product design 
Each route of drug administration has special biopharmaceutical 
considerations which should be taken into account while designing the drug dosage 
form (Table 1.1 ). 
An interesting example is the systemic drug absorption from an extravascular 
site and from oral route. This absorption is affected by: 
1. The anatomic and physiologic properties of the target site. 
2. The physicochemical properties of the drug and the drug product. 
3. The anatomy, physiology, and the contents of the gastrointestinal tract 
(GIT) (Shargel and Yu, 1999). 
All of these factors should be considered in the design of a drug product for 
oral administration. Biopharmaceutic studies usually use the in vitro or in vivo 
methods. In vitro methods are used to: 
a) Understand the physico-chemical properties of the drug and drug product. 
b) Evaluate the quality of the manufacturing process. 
Finally, the drug must be studied in vivo, in humans, to evaluate different 
aspects of drug formulation and delivery by studying the pharmacodynamics, 
pharmacokinetics, therapeutics, and toxicity of the drug product. 
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Table 1.1 Common routes of drug administration and their advantages and disadvantages. [Adapted from Swarbrick (2007).] 
Route ' Bioavailability Advantages Disadvantages 
Intravenous Complete ( 1 00%) systemic drug Drug is given for immediate effect Increased chance of adverse 
bolus (IV) absorption. Rate of bioavailability reaction. Possibility of 
considered instantaneous anaphylaxis 
Intravenous Complete (100%) systemic drug Plasma drug levels more precisely Requires skill in insertion of 
infusion (IV absorption Controlled. May inject large infusion set 
inf) fluid volumes 
Rate of drug absorption controlled by Tissue damage at the site of I 
<'-l infusion pump May use drugs with poor lipid injection (infiltration, necrosis, ~ 
..... 
solubility and/or irritating drugs or sterile abscess) 
= 0 
-
= 
-
~ 
..... 
= ~ Intramuscular Rapid from aqueous solution Slow Easier to inject than intravenous Irritating drugs may be very 
-= ~ injection (IM) absorption from non-aqueous (oil) Injection painful 
solutions 
Larger volumes may be used Different rates of absorption 
compared to subcutaneous solution depending upon muscle group 
injected and blood flow 
Subcutaneous Prompt from aqueous solution. Self-administration is allowed. Rate of drug absorption depends 
injection (SC) Slow absorption from repository (depot) Generally, used for insulin upon blood flow and injection 
formulations injection volume 
--- ---- --- ---- ----------------- -------- -------- ------------
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Table 1.1 (continued) Common routes of drug administration and their advantages and disadvantages [Adapted from Swarbrick (2007)] 
Route Bioavailability Advantages Disadvantages 
Oral Absorption may vary. Generally, slower Safest and easiest route of drug Some drugs may have erratic 
absorption rate compared to IV bolus or Administration. May use absorption, unstable in the 
IM injection. Immediate-release and modified- gastrointestinal tract or 
<'-! 
~ release drug products. metabolized by liver prior to .... 
= systemic absorption Q 
-
Rectal Absorption may vary from suppository Useful when patient cannot Absorption may be erratic. eo= 
-
swallow medication Suppository may migrate to ~ 
.... 
= More reliable absorption from enema different position. ~ (solution) Used for local and systemic effects 
Some patients feel discomfort. 
Transdermal Slow absorption. Transdermal delivery system Some irritation by patch or drug. 
Absorption rate may vary. (patch) is easy to use Permeability of skin varies with 
condition, anatomic site, age, 
Increased absorption with occlusive Used for lipid-soluble drugs with and gender. 
~ dressing low dose and low molecular ~ 
.... 
= weight Type of cream or ointment base Q 
-
affects drug release and 
-
~ 
absorption . ..s:: 
.... 
Inhalation Rapid absorption. May be used for local Particle size of drug determines 0 
or systemic effects anatomic placement in 
Total dose absorbed varies. respiratory tract. 
May stimulate cough reflex. 
Some drug may be swallowed. 
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There are some major biopharmaceutical topics for research and regulatory 
considerations in drug development including drug dissolution, absorption, 
metabolism and interaction with food and other components in the GIT (Shargel and 
Yu, 1999 and Wise, 2000). 
By choosing the suitable route of drug administration and proper design of 
the drug product, drug's bioavailability can be varied from rapid to slow, to obtained 
complete systemic drug absorption and sustained rate of absorption (Wise, 2000). 
Systemic drug absorption is followed by distribution and elimination processes 
which usually are not affected by the formulation of the drug. To get the desired 
release of the drug which determine the onset, intensity and duration of drug action, 
two important parameters should be change, i.e. the rate of drug release from the 
product and the rate of drug absorption (Shargel and Yu, 1999 and Wise, 2000). 
1.1.2 Oral drug absorption: Physiologic considerations 
Drugs may be administered by different routes (Table 1.1 ). All drugs are 
absorbed into the systemic circulation from the site of administration. The only 
exception to this rule is the intravenous route which is considered to have complete 
or 100% bioavailability since the drug is placed directly into the systemic 
circulation(Li and Jasti, 2004 ). The other routes are greatly affected by the conditions 
at the site of administration. The most common route of drug administration is the 
oral route (Table 1.1 ). Understanding the physiological considerations of the GI 
system can help us in the dosage form design. Major physiologic processes that 
occur in the GI system are secretion, digestion and absorption (Krowczynski, 1987 
and Li and Jasti, 2004). 
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a) Secretion is the transport of fluid, electrolytes, peptides, and proteins into 
the lumen of the alimentary canal. Enzymes in saliva and pancreatic secretions are 
excluded because they are involved in the digestion of carbohydrates and proteins 
(Krowczynski, 1987). Other secretions such as mucus which protects the linings of 
the lumen of the GIT also are not included in the definition. 
b) Digestion is defmed as the breakdown of food constituents into smaller 
structures in preparation for absorption. The process of absorption is defmed as the 
entry of constituents from the lumen of the gut into the body (Krowczynski, 1987). 
c) Absorption may be defined in another way as the net result of both lumen-
to-blood and blood-to-lumen transport movements (Wise, 2000). Most of the drugs 
and food constituents are absorbed in the proximal area (duodenum) of the small 
intestine. 
When a drug is taken orally, it passes through various parts of the enteral 
canal including the oral cavity, esophagus, and the other parts of the GIT. Residues 
and undigested food exit the body through the anus. Drugs are absorbed from all 
parts of the alimentary canal by passive diffusion but the major sites lie in duodenum 
and jejunum (Wise, 2000). 
The optimum site for drug absorption, after oral administration is the upper 
portion of the small intestine or duodenum. Due to its unique anatomy, the 
duodenum provides a very large surface area for the drug to diffuse passively. 
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The total time a drug is retained in the GIT is an important factor for 
biopharmaceutic studies and thus this transit of drug can be broadly divided into: 
1) Total transit time, which includes gastric emptying, small intestinal transit, 
and colonic transit. 
2) Small intestine transit time (SITT). 
The total transit time ranges from 0.4 to 5 days while the small intestine 
transit time ranges from 3 to 4 h in most healthy subjects (Li and Jasti,2004, 
Swarbrick,2007). The drug absorption might be erratic or incomplete if the 
absorption is not completed within the small intestine transit time (SITT). This is 
because the small intestine is normally filled with digestive juices and liquids, which 
keep the lumen contents as fluid. When the lumen content reaches the colon the fluid 
is reabsorbed and the lumen content become semisolid or solid. This makes the drug 
dissolution erratic and difficult (Li and Jasti, 2004). 
1.1.2.1 GI motility 
GI motility causes the drug to move through the alimentary canal. If the drug 
is formulated as a non-biodegradable controlled-release dosage form it should get 
completely released into this absorption window before the movement into the large 
bowel. It is important because the drug might not stay at the absorption site and thus 
result in incomplete absorption (Swarbrick, 2007). 
Some drugs are only soluble at a particular pH or they are absorbed using a 
specific mechanism. With such properties those drugs can only be absorbed in 
specific segments of the GI tract. Those particular segments are named "absorption 
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windows". Any factors which effectively increase or decrease the Gastric emptying 
time and the SITT (small intestinal transit time) will affect the drug absorption from 
its absorption window(Swarbrick, 2007). 
The transit time of the drug in the GIT depends on the Pharmacological 
properties of the drug, type of dosage form and various physiological factors such as 
the alimentary canal state that includes digestive or fed state, fasted state or inter-
digestive state. 
1.1.2.1.1 Gastric emptying time 
Since the duodenum has the greatest capacity for the absorption of drugs 
from the GIT, a delay in the gastric emptying time can slow the rate and possibly the 
extent of drug absorption from the duodenum, thereby prolonging the absorption of 
the drug. Factors that tend to delay gastric emptying include consumption of high fat 
meals, cold beverages, and anticholinergic drugs. 
1.1.2.1.2 Intestinal motility 
The drug must have a sufficient resident time at the site of absorption for 
optimum absorption. In the case of high motility in the intestinal tract, as in diarrhea, 
the drug has a very brief residence time and less opportunity for adequate absorption. 
1.1.2.2 Blood perfusion of the GIT 
Either the blood carries the absorbed drug from the absorption site to the 
systemic circulation directly or drugs are absorbed from the small intestine into the 
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mesenteric vessels which flow to the hepatic-portal vein and then to the liver prior to 
reaching the systemic circulation, this is known as first pass effect. 
The rate of systemic drug absorption from the intestinal tract will decrease if 
there is any decrease in mesenteric blood flow, as in the case of congestive heart 
failure. Microvilli in the intestinal lining possess lymphatic ducts that play a role in 
the absorption of the dietary lipids and possibly some lipophilic drugs. Such 
drugs,that are absorbed through the lymphatic vessels (passing the first pass effect), 
are not metabolized in the liver prior to entering blood circulation. 
1.1.2.3 Effect of food and other factors on GI drug absorption 
Digested foods may affect the intestinal pH and solubility of drugs. Food 
effects are not always predictable. Food in the GI lumen stimulates the flow of bile, 
that contains bile acids which act as surfactants. These acids are involved in the 
digestion and solubilization of fats and lipophilic drugs by increasing their solubility 
through micelle formation. 
However the presence of food in the stomach together with some basic drugs 
possessing limited aqueous solubility (e.g. cinnarizine) stimulate hydrochloric acid 
secretion, which lowers the pH, causing rapid dissolution of the drug and better 
absorption. Generally, the bioavailability of drugs is better in patients in the fasted 
state and with a large volume of water (Swarbrick, 2007). 
The drug dosage form may also be affected by food. For example, enteric-
coated tablets may stay in the stomach for a longer period of time because food 
10 
delays stomach emptying (Shargel and Yu, 1999). If the enteric-coated tablet does 
not reach the duodenum rapidly, drug release and subsequent systemic drug 
absorption are delayed. In contrast, enteric-coated beads or microparticles that 
disperse in the stomach, are less affected by food, and demonstrate more consistent 
drug absorption from the duodenum(Li and Jasti, 2004). 
Food may also affect the integrity of the dosage form, causing an alteration in 
the release rate of the drug. For example, theophylline bioavailability from Theo-24® 
controlled-release tablets is much more rapid when given to a subject in the fed 
rather than fasted state(Wise, 2000). 
Drugs or nutrients or both may also affect the absorption of other drugs. For 
example, propantheline bromide is an anticholinergic drug that slows stomach 
emptying and motility of the small intestine and may reduce stomach acid secretion. 
Grapefruit juice was found to increase the plasma level of many drugs due to 
inhibition of their metabolism in the liver (Swarbrick, 2007). 
1.1.3 Oral drug absorption: Pharmaceutical factors affecting drug 
bioavailability 
-Different biopharmaceutical considerations in the design and manufacture 
stage affect the drug product to deliver the active ingredient with the desired 
bioavailability. These factors include: the type of drug product e.g., tablet, capsule, 
solid dispersion etc; the nature of the excipients in the drug product, the 
physicochemical properties of the drug molecule and the route of drug 
administration. 
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1.1.3.1 Dissolution 
Dissolution is the process by which a chemical or drug becomes dissolved in 
a solvent. In human bodies, drug dissolution in an aqueous medium is an important 
prior condition of systemic absorption (Banakar, 1992). The rate of dissolution of the 
solid dosage form in the GIT often controls the rate of systemic absorption of the 
drug. Thus, "dissolution tests can discriminate the formulation factors that may affect 
drug bioavailability "(Swarbrick, 2007). 
The rate of dissolution, (dC/dt) x (1/A), is the amount of drug dC dissolved 
per unit area A per time dt (e.g., g/cm2 per min) (Swarbrick, 2007, Banakar, 1992). 
The Noyes-Whitney equation shows that dissolution rate is influenced by: the 
physicochemical characteristics of the drug, the formulation of the drug, the solvent, 
the temperature of the medium and the agitation strength (Banakar, 1992). 
A dissolution test in vitro gives us information about the rate and extent of 
drug dissolution in an aqueous medium in the presence of the excipients contained in 
the drug product. Choosing unsuitable dissolution method may lead to a potential 
bioavailability problem. Dissolution testing conditions differ with each drug 
formulation depending upon agitation rates, medium (including pH) and simulating 
technique (basket, paddles and others) 
The nature of the dissolution medium, the solubility the drug and the amount 
of drug in the dosage form all can affect the dissolution test (Banakar, 1992, Wise, 
2000). 
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1.1.3.2 Physicochemical nature of the drug 
1.1.3.2.1 Solubility, pH, and drug absorption 
The natural pH of the GIT environment varies from acidic in the stomach to 
slightly alkaline in the small intestine. Drug solubility may be improved or delayed 
with the addition of acidic, basic, or lipid excipients. For relatively insoluble 
compounds the dissolution rate is often the rate-determining step in the overall 
absorption process. Alternatively, for soluble compounds the rate of permeation 
across biological membrane is the rate-determining step. 
To protect the physically or chemically unstable drugs from degradation, 
special excipients, coating or manufacturing process may be used. Controlled release 
drug products are non-disintegrating dosage forms and buffering agents may be 
added to slow or modify the release rate of a fast-dissolving drug (Wise, 2000). 
The buffering agent can be defined as an agent when is solution form will 
maintains pH of a solution at a constant value when small amounts of acidic or basic 
substances are added. To function in this manner, a buffer solution will necessarily 
contain either a weak acid and its conjugate base, or a weak base and its conjugate 
acid. The added buffering agents play its role when it is released slowly rather than 
rapidly so that the drug does not dissolve immediately in the surrounding GI fluid 
(Swarbrick, 2007). 
1.1.3.2.2 Stability, pH, and drug absorption 
The pH-stability profile is "a plot of reaction rate constant for drug 
degradation versus pH" (Swarbrick, 2007) and it helps to predict if some of the drug 
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will decompose in the GIT. For example, the stability of erythromycin is pH-
dependent. In acidic medium, erythromycin decomposes rapidly, whereas at neutral 
or alkaline pH the drug is relatively stable. As a result, erythromycin tablets are 
enterically coated to protect against acidic degradation in the stomach 
( Krowczynski, 1987,Schreier, 2001). 
Drug partition coefficients is important to predict how well it will be able to 
cross biological membranes. The measure of drug's partition coefficient between an 
oil and water phase (log P) gives a measure of the lipophilicity of the drug. 
1.1.3.2.3 Particle size and drug absorption 
The effective surface area of the drug is increased enormously by reducing 
the particle size which can lead to rapid dissolution rate of drug. Although the 
geometric shape of the drug particle affects the surface area, and during dissolution 
the surface changes constantly during dissolution, the solute particle is usually 
assumed to have retained its geometric shape for the purpose of dissolution 
calculations (Banakar, 1992, Swarbrick, 2007). 
Studies of particle size and particle size distribution are important for drugs 
that haye low water solubility. Smaller particles will have higher total effective or 
specific surface area which enhances contact with water penetration into the particles 
leading to increases in the dissolution rates(Shargel and Yu, 1999). 
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1.1.3.2.4 Polymorphic crystals, solvates, and drug absorption 
Polymorphism refers to the arrangement of a drug in various crystal forms 
(polymorphs). Polymorphs have the same chemical structure but different physical 
properties, such as solubility, density, hardness, and compression characteristics 
(Schreier, 2001). Some polymorphic crystals may have much lower aqueous 
solubility than the amorphous forms, causing a product to be incompletely absorbed. 
In general, the crystal form that has the lowest free energy is the most stable 
polymorph. Polymorphs that are meta-stable may convert to a more stable form over 
time. A change in crystal form may cause problems in manufacturing the product. 
For example, a change in crystal structure of the drug may cause cracking in a tablet 
or even prevent granules from being compressed into a tablet resulting in a need to 
reformulate of the product (Wise, 2000). 
1.1.4 Formulation factors affecting drug dissolution 
Excipients are pharmacodynamically inactive substances that are added to a 
formulation to provide certain functional properties to the drug and dosage form. 
Excipients may be added to stabilize the drug, prevent from degradation, control the 
rate of drug absorption from the absorption site and increase drug bioavailability, etc. 
Improp_er use of excipients may lead to altered drug bioavailability and 
pharmacodynamic activity. They may affect the drug dissolution rate by altering the 
medium in which the drug is dissolved or by drug-excipient interaction (Swarbrick, 
2007) and may enhance or diminish the rate and extent of systemic drug absorption. 
Those which increase the aqueous solubility of the drug generally increase the rate of 
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drug dissolution and absorption and may interact directly with the drug to form a 
water-soluble or water-insoluble complex (Shargel and Yu, 1999, Schreier, 2001). 
Excipients may increase the retention time of the drug in the GIT and 
therefore increase the amount of drug absorbed. Some of them may act as carriers to 
increase drug diffusion across the intestinal wall. The addition of surface-active 
agents may increase wetting as well as solubility of drugs. In contrast, many 
excipients may retard drug dissolution and thus reduce drug absorption (Florence and 
Attwood, 2006). For example Shellac used as a tablet coating, upon aging, can slow 
the drug dissolution rate (Lirnmatvapirat et al., 2004). 
Surfactants affect the drug solution according to its concentration, low 
concentrations of surfactants lower the surface tension and increase the rate of drug 
dissolution, whereas higher concentrations of surfactants tend to form micelles with 
the drug and thus decrease the dissolution rate (Florence and Attwood, 2006). 
1.2 Controlled release 
Conventional solid pharmaceutical dosage forms, like tablets and other 
traditional pharmaceutical products are still commonly seen today in the prescription 
and over-the-counter drug market place. Such types of drug delivery systems often 
necessitate repeated and short dosage intervals to achieve and maintain the drug 
concentration in therapeutic index range. This yields an undesirable "seesaw" drug 
level in the body (for drugs with short t112, tmax and high absorption rate) as shown by 
Figure 1.1, thus the release of such drugs should be modified to increase the t112, trnax 
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and slow down the absorption rate. This could lead to large dosage intervals and 
reduction in the frequency of dosing. 
c: 
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Figure 1.1 Drug concentration profiles in the systemic circulation as a result of 
taking a series of multiple doses of a conventional drug-delivery system( for drugs 
with short t112, tmax and high absorption rate) (AI, A2, A3, A4 ..... ) in comparison 
with the ideal drug concentration profile (B). 
[Adapted from (Chien, 1992)] 
USP pharmacopeia define the Extended release tablets as they are "formulated in 
such manner as to make the contained medicament available over an extended period 
of time following ingestion" and allows a twofold reduction in dosing frequency or 
increase in patient compliance or therapeutic performance. It is interesting to note 
that the USP considers that the terms repeat action, prolonged release and sustained 
release are interchangeable with extended release. While controlled release give us a 
dosage form release drug at a constant rate and provide plasma concentrations that 
remain invariant with time (U.S.Pharmacopoeia, 2007). 
1.2.1 Advantages of controlled release systems 
A number of advancements have been made recently in the development of 
new techniques for drug delivery. These techniques are capable of regulating the rate 
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of drug delivery, sustaining the duration of therapeutic action, and/or targeting the 
drug to specific tissue (Craig, 2002) 
These advancements have already resulted in the development of several 
novel drug delivery systems that could provide one or more of the following benefits: 
a) Controlled administration of a therapeutic dose at a desirable rate of 
delivery 
b) Maintenance of drug concentration within an optimal therapeutic range for 
prolonged duration of treatment 
c) Maximization of efficacy-dose relationship 
d) Reduction of adverse side effects 
e) Minimization of the needs for frequent dose intake 
f) Enhancement of patient compliance. 
1.2.2 Classification of controlled release systems 
According to the encyclopedia of pharmaceutical technology, controlled 
release systems which are based on the technical sophistication of the controlled-
release drug delivery systems (CrDDSs) that have been marketed so far or that are 
under active development can be classified as follow: 
-a) Rate-preprogrammed drug delivery systems 
b) Activation-modulated drug delivery systems 
c) Feedback-regulated drug delivery systems 
d) Site-targeting drug delivery systems 
As shown in plate 1.1, the scientific concepts and technical principles behind the 
development of this new generation of drug-delivery systems are outlined 
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1.2.2.1 Rate-preprogrammed drug delivery systems 
"In this group of CrDDSs, the release of drug molecules from the delivery 
systems has been preprogrammed at a specific rate profile. This is accomplished by 
system design, which controls the molecular diffusion of drug molecules in and/or 
across the barrier medium within or surrounding the delivery system. Pick's laws of 
diffusion are often followed"(Swarbrick, 2007). 
These CrDDSs can further be classified as follow: 
1. Polymer membrane permeation-controlled drug delivery systems. 
2. Polymer matrix diffusion-controlled drug delivery systems. 
3. Polymer (membrane/matrix) hybrid-type drug delivery systems. 
4. Micro-reservoir partition-controlled drug delivery systems. 
1.2.2.1.1 Polymer membrane permeation-controlled drug delivery systems 
"In this type of CrDDSs, a drug formulation is either totally or partially 
encapsulated in a drug reservoir compartment whose drug-releasing surface is 
covered by a rate-controlling polymeric membrane"(Swarbrick, 2007). 
The drug reservoir can be: 
1. Drug solid particles. 
2. Dispersion of drug solid particles. 
3. Concentrated drug solution in a liquid. 
4. Solid-type dispersing medium. 
The polymeric membrane can be fabricated from different types of materials 
for example; homogeneous or heterogeneous polymeric material, non-porous, 
microporous or semi-permeable membrane. 
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RATE-PREPROGRAMMED DRUG DELIVERY SYSTEMS 
Polymer membrane permeation-controlled drug delivery systems 
Polymer (membrane/matrix) hybrid-type drug delivery systems 
Microreservoir partition-controlled drug delivery systems 
ACTIVATION-MODULATED DRUG DELIVERY SYSTEMS 
Osmotic Pressure-Activated Drug Delivery Systems 
Hydrodynamic Pressure-Activated Drug Delivery Systems 
Magnetic-Activated Drug Delivery Systems 
Sonophoresis-Activated Drug Delivery Systems 
Iontophoresis-Activated Drug Delivery Systems 
Hydration-Activated Drug Delivery Systems 
pH-Activated Drug Delivery Systems 
Ion-Activated Drug Delivery Systems 
Hydrolysis-Activated Drug Delivery Systems 
Progestasert _ IUD 
Ocusert_ system 
Transderm-Nitro_ system 
Norplant_ subdermal implant 
Nitro-Our_ system 
Compudose_ implant 
Nitrodisc _ system 
Syncro-Mate-C implant 
Transdermal contraceptive device 
Alzet osmotic pump 
Acutrim_ tablet 
Syncro-Male-B implant 
Valrelease _ tablet 
1 
Plate 1.1 Classification of controlled release drug delivery systems. [Adapted from (Swarbrick, 2007 and Wise, 2000)] with modifications. 
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FEEDBACK-REGULATED DRUG DELIVERY SYSTEMS 
Bioerosion-Regulated Drug Delivery Systems 
Bioresponsive Drug Delivery Systems 
Self-Regulating Drug Delivery Systems 
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Plate 1.1 (continued) Classification of controlled release drug delivery systems. [Adapted from (Swarbrick, 2007 and Wise, 2000) ] with 
modification. 
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The encapsulation of drug into the reservoir compartment can be done by 
different techniques for example; molding, capsulation or micro-encapsulation to 
form different shapes and sizes of drug delivery systems, (Figure 1.2). 
Different factors control the release of drug molecules from this type of 
CrDDS. These include partition coefficient, diffusivity of drug molecule, rate-
controlling membrane and thickness of the membrane. 
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Figure 1.2 Release of drug from various shapes of polymer membrane permeation-
controlled drug-delivery systems: (A) sphere-type, (B) cylinder-type, and (C) sheet-
type. In (D), the drug concentration gradients across the rate-controlling polymeric 
membrane and hydrodynamic diffusion layer exist in series. Both the polymer 
membrane, which is either porous or non-porous, and the diffusion layer have a 
controlled thickness (hm and hd, respectively). 
[Adapted from (Swarbrick, 2007)] 
1.2.2.1.2 Polymer matrix diffusion-controlled drug delivery systems 
"In this type of CrDDSs, the drug reservoir is produced from the 
homogeneous dispersion of drug particles in either a lipophilic or a hydrophilic 
polymer matrix"(Swarbrick, 2007). 
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The drug dispersion in the polymer matrix is accomplished by either 
blending a dose of finely ground drug particles with a viscous liquid (or a semisolid) 
polymer, followed by a crosslinking of polymer chains, such as; sodium alginate and 
the calcium chloride solution or mixing solid drugs with a molten polymer at an 
elevated temperature for example; Gelucires. 
The resultant drug-polymer dispersion is then molded or extruded to form 
drug delivery devices of various shapes and sizes designed for a specific application 
(Figure.l.3). Another way to achieve this dispersion is by dissolving the drug and the 
polymer in a common solvent, followed by solvent evaporation, at an elevated 
temperature and/or under a vacuum, in a mold. 
Factors that control the release of drug molecules from this type of CrDDSs 
are the loading level, polymer solubility of the drug, and the diffusivity ofthe drug in 
the polymer matrix. Several CrDDSs of this type have been successfully marketed 
for therapeutic uses. 
1.2.2.1.3 Polymer (membrane/matrix) hybrid-type drug delivery systems 
"This type of CrDDSs, is developed with the objective of combining the 
constant drug release kinetics of polymer membrane permeation-controlled drug 
delivery systems with the mechanical superiority of polymer matrix diffusion-
controlled drug delivery systems" (Swarbrick, 2007). 
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1.2.2.1.4 Micro-reservoir partition-controlled dmg delivery systems 
"In this type of CrDDSs, the drug reservoir is a suspension of drug solid 
particles in an aqueous solution of a water-miscible polymer, like polyethylene 
glycols" (Swarbrick, 2007). Different shapes and sizes of drug-delivery devices can 
be prepared from this micro-reservoir-type CrDDS by molding or extrusion 
techniques (Chien, 1992). 
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Figure 1.3 Release of drug from the polymer matrix diffusion controlled drug 
delivery systems with drug reservoir exists as a homogeneous dispersion in (A) 
lipophilic, non-swellable polymer matrix, with a growing thickness of drug depletion 
zone, or (B) a hydrophilic, swellable polymer matrix, with a growing thickness of 
drug-depleted gel layer. In (C), the drug concentration gradients across the time-
dependent drug depletion zone, with a growing thickness (hp dhp ), and the 
hydrodynamic diffusion layer, with a controlled thickness (hd), are shown in series. 
[Adapted from (Swarbrick, 2007)] 
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